<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02485340</url>
  </required_header>
  <id_info>
    <org_study_id>H-6-2014-071</org_study_id>
    <nct_id>NCT02485340</nct_id>
  </id_info>
  <brief_title>The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache</brief_title>
  <official_title>The Effect of Sumatriptan and Placebo on Isosorbide-5-mononitrate Induced Headache. Development of a Pragmatic Migraine Model</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Danish Headache Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Danish Headache Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To develop a pragmatic migraine model the investigators will induce headache in healthy
      volunteers and in patients with migraine without aura with a long lasting Nitrogen Oxide (NO)
      donor. If the headache responds to sumatriptan, the model can be used to test new drug
      candidates.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There remains a great need for more effective anti-migraine drugs with fewer side effects.
      Human experimental models are valuable in early phase development of new anti-migraine drugs
      but useful models have not yet been developed. The investigators' group has shown that
      Isosorbide-5-mononitrate (5-ISMN), a long lasting NO-donor, induce headache/migraine in both
      healthy volunteers and in patients with migraine without aura (MO). To validate this model,
      the headache must respond to specific migraine treatment with sumatriptan.

      Hypothesis: 5-ISMN induces a migraine-like headache in both healthy subjects and in
      MO-patients and induced headache responds to a specific anti migraine drug; sumatriptan.

      Aim: Developing a pragmatic and valid model for the testing of new anti-migraine drugs
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">August 2015</completion_date>
  <primary_completion_date type="Actual">August 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median headache score 0 hours after sumatriptan/placebo</measure>
    <time_frame>0 hours</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Median headache score 2 hours after sumatriptan/placebo</measure>
    <time_frame>2 hours</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>Sumatriptan</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of sumatriptan 50 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>headache is induced with 5-ISMN. This headache is treated double-blinded with 1 tablet of placebo (the tablet is similar to the active tablet)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-ISMN (isosorbide-5-mononitrate)</intervention_name>
    <description>5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan</description>
    <arm_group_label>Sumatriptan</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Imdur</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sumatriptan</intervention_name>
    <description>5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan</description>
    <arm_group_label>Sumatriptan</arm_group_label>
    <other_name>Imigran</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>5-ISMN is given both study days to induce headache. One day the headache is treated with placebo and the other day with sumatriptan</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy:

          -  healthy subjects of both sexes

          -  age 18-70 years

          -  weight 50-90 kg.

          -  Females were requested to use effective contraception.

        Migraine patients:

          -  Migraine patients who meet International headache society (IHS) criteria for migraine
             with or without aura of both sexes

          -  18-70 years

          -  45-95 kg.

        Exclusion Criteria:

        Healthy:

          -  Any type of headache (except episodic tension-type headache &lt; 1 day per week)

          -  Serious somatic or psychiatric disease

          -  Pregnancy

          -  Intake of daily medication (except oral contraceptives).

        Migraine patients:

          -  Any other type of headache then migraine without aura (except episodic tension-type
             headache &lt; 1 day per week)

          -  Serious somatic or psychiatric disease

          -  Pregnancy, and intake of daily medication (except oral contraceptives).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Emma Katrine Hansen, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Danish Headache Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emma Katrine Hansen</name>
      <address>
        <city>Copenhagen</city>
        <state>Glostrup</state>
        <zip>2600</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 4, 2015</study_first_submitted>
  <study_first_submitted_qc>June 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2015</study_first_posted>
  <last_update_submitted>January 21, 2016</last_update_submitted>
  <last_update_submitted_qc>January 21, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Danish Headache Center</investigator_affiliation>
    <investigator_full_name>Emma Katrine Hansen</investigator_full_name>
    <investigator_title>Medical doctor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sumatriptan</mesh_term>
    <mesh_term>Isosorbide</mesh_term>
    <mesh_term>Isosorbide-5-mononitrate</mesh_term>
    <mesh_term>Isosorbide Dinitrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

